HEADER CELL CYCLE/INHIBITOR 21-APR-17 5VKG TITLE SOLUTION-STATE NMR STRUCTURAL ENSEMBLE OF HUMAN TSG101 UEV IN COMPLEX TITLE 2 WITH TENATOPRAZOLE COMPND MOL_ID: 1; COMPND 2 MOLECULE: TUMOR SUSCEPTIBILITY GENE 101 PROTEIN; COMPND 3 CHAIN: A; COMPND 4 SYNONYM: ESCRT-I COMPLEX SUBUNIT TSG101; COMPND 5 ENGINEERED: YES; COMPND 6 MUTATION: YES SOURCE MOL_ID: 1; SOURCE 2 ORGANISM_SCIENTIFIC: HOMO SAPIENS; SOURCE 3 ORGANISM_COMMON: HUMAN; SOURCE 4 ORGANISM_TAXID: 9606; SOURCE 5 GENE: TSG101; SOURCE 6 EXPRESSION_SYSTEM: ESCHERICHIA COLI; SOURCE 7 EXPRESSION_SYSTEM_TAXID: 562; SOURCE 8 EXPRESSION_SYSTEM_STRAIN: ROSETTA 2 (DE3); SOURCE 9 EXPRESSION_SYSTEM_PLASMID: PET-28B KEYWDS ESCRT-I, INHIBITOR, CELL CYCLE, CELL CYCLE-INHIBITOR COMPLEX EXPDTA SOLUTION NMR NUMMDL 20 AUTHOR M.STRICKLAND,L.S.EHRLICH,S.WATANABE,M.KHAN,M.-P.STRUB,C.H.LUAN, AUTHOR 2 M.D.POWELL,J.LEIS,N.TJANDRA,C.CARTER REVDAT 3 14-JUN-23 5VKG 1 REMARK REVDAT 2 22-NOV-17 5VKG 1 JRNL REVDAT 1 15-NOV-17 5VKG 0 JRNL AUTH M.STRICKLAND,L.S.EHRLICH,S.WATANABE,M.KHAN,M.P.STRUB, JRNL AUTH 2 C.H.LUAN,M.D.POWELL,J.LEIS,N.TJANDRA,C.A.CARTER JRNL TITL TSG101 CHAPERONE FUNCTION REVEALED BY HIV-1 ASSEMBLY JRNL TITL 2 INHIBITORS. JRNL REF NAT COMMUN V. 8 1391 2017 JRNL REFN ESSN 2041-1723 JRNL PMID 29123089 JRNL DOI 10.1038/S41467-017-01426-2 REMARK 2 REMARK 2 RESOLUTION. NOT APPLICABLE. REMARK 3 REMARK 3 REFINEMENT. REMARK 3 PROGRAM : X-PLOR NIH 2.37.7 REMARK 3 AUTHORS : SCHWIETERS, KUSZEWSKI, TJANDRA AND CLORE REMARK 3 REMARK 3 OTHER REFINEMENT REMARKS: NULL REMARK 4 REMARK 4 5VKG COMPLIES WITH FORMAT V. 3.30, 13-JUL-11 REMARK 100 REMARK 100 THIS ENTRY HAS BEEN PROCESSED BY RCSB ON 24-APR-17. REMARK 100 THE DEPOSITION ID IS D_1000227070. REMARK 210 REMARK 210 EXPERIMENTAL DETAILS REMARK 210 EXPERIMENT TYPE : NMR REMARK 210 TEMPERATURE (KELVIN) : 300; 300 REMARK 210 PH : 5.8; 5.8 REMARK 210 IONIC STRENGTH : 0.1; 0.1 REMARK 210 PRESSURE : 1 ATM; 1 ATM REMARK 210 SAMPLE CONTENTS : 0.6 MM [U-98% 13C; U-98% 15N] REMARK 210 TSG101, 0.6 MM TENATOPRAZOLE, 20 REMARK 210 MM POTASSIUM PHOSPHATE, 50 MM REMARK 210 SODIUM CHLORIDE, 93% H2O/7% D2O; REMARK 210 0.6 MM [U-13C; U-15N] TSG101, REMARK 210 0.6 MM TENATOPRAZOLE, 20 MM REMARK 210 POTASSIUM PHOSPHATE, 50 MM REMARK 210 SODIUM CHLORIDE, 100% D2O REMARK 210 REMARK 210 NMR EXPERIMENTS CONDUCTED : 2D 1H-15N HSQC; 2D 1H-13C HSQC REMARK 210 ALIPHATIC; 3D HNCACB; 3D H(CCO) REMARK 210 NH; 3D 1H-15N NOESY; 3D 1H-13C REMARK 210 NOESY ALIPHATIC; 3D 1H-13C NOESY REMARK 210 AROMATIC; 3D 1H-13C-12C FILTERED REMARK 210 NOESY ALIPHATIC; 3D CBCA(CO)NH; REMARK 210 3D C(CO)NH REMARK 210 SPECTROMETER FIELD STRENGTH : 600 MHZ; 800 MHZ; 900 MHZ REMARK 210 SPECTROMETER MODEL : AVANCE REMARK 210 SPECTROMETER MANUFACTURER : BRUKER REMARK 210 REMARK 210 STRUCTURE DETERMINATION. REMARK 210 SOFTWARE USED : TOPSPIN 3.0, NMRPIPE 8.2, REMARK 210 NMRDRAW 8.2, ANALYSIS 2.4.2, REMARK 210 PSVS 1.5, GAUSSIAN 9, TALOS-N REMARK 210 4.12, X-PLOR NIH 2.37.7 REMARK 210 METHOD USED : SIMULATED ANNEALING REMARK 210 REMARK 210 CONFORMERS, NUMBER CALCULATED : 100 REMARK 210 CONFORMERS, NUMBER SUBMITTED : 20 REMARK 210 CONFORMERS, SELECTION CRITERIA : STRUCTURES WITH THE LOWEST REMARK 210 ENERGY REMARK 210 REMARK 210 BEST REPRESENTATIVE CONFORMER IN THIS ENSEMBLE : 1 REMARK 210 REMARK 210 REMARK: NULL REMARK 215 REMARK 215 NMR STUDY REMARK 215 THE COORDINATES IN THIS ENTRY WERE GENERATED FROM SOLUTION REMARK 215 NMR DATA. PROTEIN DATA BANK CONVENTIONS REQUIRE THAT REMARK 215 CRYST1 AND SCALE RECORDS BE INCLUDED, BUT THE VALUES ON REMARK 215 THESE RECORDS ARE MEANINGLESS. REMARK 300 REMARK 300 BIOMOLECULE: 1 REMARK 300 SEE REMARK 350 FOR THE AUTHOR PROVIDED AND/OR PROGRAM REMARK 300 GENERATED ASSEMBLY INFORMATION FOR THE STRUCTURE IN REMARK 300 THIS ENTRY. THE REMARK MAY ALSO PROVIDE INFORMATION ON REMARK 300 BURIED SURFACE AREA. REMARK 350 REMARK 350 COORDINATES FOR A COMPLETE MULTIMER REPRESENTING THE KNOWN REMARK 350 BIOLOGICALLY SIGNIFICANT OLIGOMERIZATION STATE OF THE REMARK 350 MOLECULE CAN BE GENERATED BY APPLYING BIOMT TRANSFORMATIONS REMARK 350 GIVEN BELOW. BOTH NON-CRYSTALLOGRAPHIC AND REMARK 350 CRYSTALLOGRAPHIC OPERATIONS ARE GIVEN. REMARK 350 REMARK 350 BIOMOLECULE: 1 REMARK 350 AUTHOR DETERMINED BIOLOGICAL UNIT: MONOMERIC REMARK 350 APPLY THE FOLLOWING TO CHAINS: A REMARK 350 BIOMT1 1 1.000000 0.000000 0.000000 0.00000 REMARK 350 BIOMT2 1 0.000000 1.000000 0.000000 0.00000 REMARK 350 BIOMT3 1 0.000000 0.000000 1.000000 0.00000 REMARK 465 REMARK 465 MISSING RESIDUES REMARK 465 THE FOLLOWING RESIDUES WERE NOT LOCATED IN THE REMARK 465 EXPERIMENT. (RES=RESIDUE NAME; C=CHAIN IDENTIFIER; REMARK 465 SSSEQ=SEQUENCE NUMBER; I=INSERTION CODE.) REMARK 465 MODELS 1-20 REMARK 465 RES C SSSEQI REMARK 465 GLY A 1 REMARK 500 REMARK 500 GEOMETRY AND STEREOCHEMISTRY REMARK 500 SUBTOPIC: TORSION ANGLES REMARK 500 REMARK 500 TORSION ANGLES OUTSIDE THE EXPECTED RAMACHANDRAN REGIONS: REMARK 500 (M=MODEL NUMBER; RES=RESIDUE NAME; C=CHAIN IDENTIFIER; REMARK 500 SSEQ=SEQUENCE NUMBER; I=INSERTION CODE). REMARK 500 REMARK 500 STANDARD TABLE: REMARK 500 FORMAT:(10X,I3,1X,A3,1X,A1,I4,A1,4X,F7.2,3X,F7.2) REMARK 500 REMARK 500 EXPECTED VALUES: GJ KLEYWEGT AND TA JONES (1996). PHI/PSI- REMARK 500 CHOLOGY: RAMACHANDRAN REVISITED. STRUCTURE 4, 1395 - 1400 REMARK 500 REMARK 500 M RES CSSEQI PSI PHI REMARK 500 1 TYR A 32 66.97 -111.07 REMARK 500 1 TYR A 63 117.54 -163.08 REMARK 500 1 ASP A 123 161.69 58.95 REMARK 500 1 GLU A 138 84.60 -163.49 REMARK 500 2 TYR A 17 55.24 -116.19 REMARK 500 2 TYR A 32 66.98 -110.56 REMARK 500 2 TYR A 63 106.42 -161.63 REMARK 500 2 ASP A 123 -175.98 48.89 REMARK 500 2 GLU A 138 84.89 -166.88 REMARK 500 3 TYR A 17 64.22 -111.28 REMARK 500 3 TYR A 32 68.45 -114.36 REMARK 500 3 TYR A 63 109.43 -163.42 REMARK 500 3 ASP A 104 -159.97 -90.54 REMARK 500 3 ASP A 123 164.92 58.54 REMARK 500 3 GLU A 138 85.43 -165.91 REMARK 500 4 TYR A 17 60.66 -110.65 REMARK 500 4 TYR A 32 67.44 -110.20 REMARK 500 4 TYR A 63 109.70 -163.70 REMARK 500 4 ASP A 123 165.59 59.28 REMARK 500 4 GLU A 138 90.91 -164.47 REMARK 500 4 PRO A 139 109.96 -44.90 REMARK 500 5 TYR A 17 58.57 -113.77 REMARK 500 5 TYR A 32 66.74 -112.70 REMARK 500 5 TYR A 63 106.96 -161.83 REMARK 500 5 ASP A 123 166.27 68.04 REMARK 500 5 GLU A 138 82.26 -155.85 REMARK 500 6 TYR A 17 55.32 -112.20 REMARK 500 6 TYR A 32 67.58 -114.56 REMARK 500 6 TYR A 63 118.84 -163.93 REMARK 500 6 ASP A 78 -9.87 -57.68 REMARK 500 6 ASP A 123 164.65 59.47 REMARK 500 7 TYR A 32 66.19 -109.78 REMARK 500 7 TYR A 63 112.61 -162.93 REMARK 500 7 ASP A 78 -18.29 -48.27 REMARK 500 7 ASP A 123 -177.84 47.82 REMARK 500 8 TYR A 32 66.93 -114.43 REMARK 500 8 TYR A 63 106.50 -162.84 REMARK 500 8 ASP A 123 167.67 65.76 REMARK 500 9 TYR A 17 70.16 -114.58 REMARK 500 9 TYR A 32 68.85 -118.24 REMARK 500 9 TYR A 63 116.08 -163.48 REMARK 500 9 ASP A 123 165.84 66.98 REMARK 500 9 GLU A 138 81.66 -157.67 REMARK 500 9 PRO A 139 109.31 -49.10 REMARK 500 10 TYR A 17 61.92 -108.18 REMARK 500 10 TYR A 32 68.14 -111.97 REMARK 500 10 TYR A 63 114.78 -163.57 REMARK 500 10 ASP A 123 164.09 69.32 REMARK 500 10 GLU A 138 83.77 -161.73 REMARK 500 11 TYR A 17 61.77 -117.94 REMARK 500 REMARK 500 THIS ENTRY HAS 102 RAMACHANDRAN OUTLIERS. REMARK 500 REMARK 500 REMARK: NULL REMARK 800 REMARK 800 SITE REMARK 800 SITE_IDENTIFIER: AC1 REMARK 800 EVIDENCE_CODE: SOFTWARE REMARK 800 SITE_DESCRIPTION: binding site for residue 4N1 A 201 REMARK 900 REMARK 900 RELATED ENTRIES REMARK 900 RELATED ID: 30285 RELATED DB: BMRB REMARK 900 SOLUTION-STATE NMR STRUCTURAL ENSEMBLE OF HUMAN TSG101 UEV IN REMARK 900 COMPLEX WITH TENATOPRAZOLE DBREF 5VKG A 1 145 UNP Q99816 TS101_HUMAN 1 145 SEQADV 5VKG GLY A 1 UNP Q99816 MET 1 ENGINEERED MUTATION SEQRES 1 A 145 GLY ALA VAL SER GLU SER GLN LEU LYS LYS MET VAL SER SEQRES 2 A 145 LYS TYR LYS TYR ARG ASP LEU THR VAL ARG GLU THR VAL SEQRES 3 A 145 ASN VAL ILE THR LEU TYR LYS ASP LEU LYS PRO VAL LEU SEQRES 4 A 145 ASP SER TYR VAL PHE ASN ASP GLY SER SER ARG GLU LEU SEQRES 5 A 145 MET ASN LEU THR GLY THR ILE PRO VAL PRO TYR ARG GLY SEQRES 6 A 145 ASN THR TYR ASN ILE PRO ILE CYS LEU TRP LEU LEU ASP SEQRES 7 A 145 THR TYR PRO TYR ASN PRO PRO ILE CYS PHE VAL LYS PRO SEQRES 8 A 145 THR SER SER MET THR ILE LYS THR GLY LYS HIS VAL ASP SEQRES 9 A 145 ALA ASN GLY LYS ILE TYR LEU PRO TYR LEU HIS GLU TRP SEQRES 10 A 145 LYS HIS PRO GLN SER ASP LEU LEU GLY LEU ILE GLN VAL SEQRES 11 A 145 MET ILE VAL VAL PHE GLY ASP GLU PRO PRO VAL PHE SER SEQRES 12 A 145 ARG PRO HET 4N1 A 201 41 HETNAM 4N1 4-METHOXY-1-(5-METHOXY-3H-IMIDAZO[4,5-B]PYRIDIN-2-YL)- HETNAM 2 4N1 3,5-DIMETHYL-2-(SULFANYLMETHYL)PYRIDIN-1-IUM FORMUL 2 4N1 C16 H19 N4 O2 S 1+ HELIX 1 AA1 SER A 4 VAL A 12 1 9 HELIX 2 AA2 TYR A 17 TYR A 32 1 16 HELIX 3 AA3 LEU A 111 GLU A 116 1 6 HELIX 4 AA4 SER A 122 PHE A 135 1 14 SHEET 1 AA1 4 LEU A 35 VAL A 43 0 SHEET 2 AA1 4 SER A 49 TYR A 63 -1 O ASN A 54 N VAL A 38 SHEET 3 AA1 4 ASN A 66 TRP A 75 -1 O ASN A 66 N TYR A 63 SHEET 4 AA1 4 ILE A 86 VAL A 89 -1 O PHE A 88 N CYS A 73 SHEET 1 AA2 2 MET A 95 ILE A 97 0 SHEET 2 AA2 2 VAL A 141 SER A 143 -1 O PHE A 142 N THR A 96 LINK SG CYS A 73 S20 4N1 A 201 1555 1555 2.03 CISPEP 1 TYR A 80 PRO A 81 1 1.78 CISPEP 2 HIS A 119 PRO A 120 1 -2.12 CISPEP 3 TYR A 80 PRO A 81 2 1.04 CISPEP 4 HIS A 119 PRO A 120 2 -2.19 CISPEP 5 TYR A 80 PRO A 81 3 0.55 CISPEP 6 HIS A 119 PRO A 120 3 -2.48 CISPEP 7 TYR A 80 PRO A 81 4 0.57 CISPEP 8 HIS A 119 PRO A 120 4 -3.04 CISPEP 9 TYR A 80 PRO A 81 5 2.44 CISPEP 10 HIS A 119 PRO A 120 5 -2.69 CISPEP 11 TYR A 80 PRO A 81 6 0.93 CISPEP 12 HIS A 119 PRO A 120 6 -2.81 CISPEP 13 TYR A 80 PRO A 81 7 1.64 CISPEP 14 HIS A 119 PRO A 120 7 -2.59 CISPEP 15 TYR A 80 PRO A 81 8 -0.27 CISPEP 16 HIS A 119 PRO A 120 8 -2.76 CISPEP 17 TYR A 80 PRO A 81 9 1.20 CISPEP 18 HIS A 119 PRO A 120 9 -2.67 CISPEP 19 TYR A 80 PRO A 81 10 1.26 CISPEP 20 HIS A 119 PRO A 120 10 -2.44 CISPEP 21 TYR A 80 PRO A 81 11 1.13 CISPEP 22 HIS A 119 PRO A 120 11 -2.28 CISPEP 23 TYR A 80 PRO A 81 12 0.86 CISPEP 24 HIS A 119 PRO A 120 12 -2.53 CISPEP 25 TYR A 80 PRO A 81 13 1.11 CISPEP 26 HIS A 119 PRO A 120 13 -2.65 CISPEP 27 TYR A 80 PRO A 81 14 1.28 CISPEP 28 HIS A 119 PRO A 120 14 -2.78 CISPEP 29 TYR A 80 PRO A 81 15 1.33 CISPEP 30 HIS A 119 PRO A 120 15 -3.23 CISPEP 31 TYR A 80 PRO A 81 16 0.80 CISPEP 32 HIS A 119 PRO A 120 16 -2.35 CISPEP 33 TYR A 80 PRO A 81 17 1.18 CISPEP 34 HIS A 119 PRO A 120 17 -2.10 CISPEP 35 TYR A 80 PRO A 81 18 0.53 CISPEP 36 HIS A 119 PRO A 120 18 -3.85 CISPEP 37 TYR A 80 PRO A 81 19 0.99 CISPEP 38 HIS A 119 PRO A 120 19 -3.04 CISPEP 39 TYR A 80 PRO A 81 20 1.64 CISPEP 40 HIS A 119 PRO A 120 20 -2.23 SITE 1 AC1 5 ASP A 40 SER A 41 THR A 56 CYS A 73 SITE 2 AC1 5 LYS A 90 CRYST1 1.000 1.000 1.000 90.00 90.00 90.00 P 1 1 ORIGX1 1.000000 0.000000 0.000000 0.00000 ORIGX2 0.000000 1.000000 0.000000 0.00000 ORIGX3 0.000000 0.000000 1.000000 0.00000 SCALE1 1.000000 0.000000 0.000000 0.00000 SCALE2 0.000000 1.000000 0.000000 0.00000 SCALE3 0.000000 0.000000 1.000000 0.00000 MODEL 1